This sounds like Al is talking about the 175 trial,but he said it three years ago.I bet he was thrilled when the FDA suggested it.

"So what does all this mean? First let me say that we will need to follow these findings with much larger trials. If the results of the larger trials support the earlier findings then I state to you that AFRESA should be used very early, certainly after failure with Metformin and as a first sign therapy for a significant portion of patients who are not candidates for Metformin or who do not do well with Metformin. It should be used well before fasting glucose is out of control and as we have seen, AFRESA even leads to lower fasting levels by eliminating the excessive gluconeogenesis.

Of course, we will have to repeat some of these findings with specific trials but we have already seen the possibilities for AFRESA as we evaluate the timing of hypos in our already completed trials to date. From what we have seen in our extensive clinical program, AFRESA should benefit the entire progression spectrum of Type II diabetes with a very simple therapy and the experts tell us that it could even stop the progression of the disease. Most of the analyst community has failed to understand that AFRESA is not just for use in basal bullous therapy but will contribute to much better therapy for the entire spectrum of Type I and Type II diabetes.

For late stage Type II’s and all Type I’s, AFRESA would be used as the more typical but superior cranial insulin basal bullous therapy. For earlier Type II patients, AFRESA alone or with Metformin would be all that would be needed to provide better control compared to other current therapies. This means that AFRESA could have value for a large segment of the 22 million diabetics in the United States and for the enormous diabetes population worldwide. To be sure, with the breadth of the market opportunity to be realized in the near future, we will have to demonstrate the benefits with new and larger trials and then develop an appropriate message to educate the market."

http://seekingalpha.com/article/170681-mannkind-corporation-q3-2009-earnings-call-transcript?find=metformin&all=false